Myelin Oligodendrocyte Glycoprotein (MOG) Antibody, CBA with Reflex to Titer

Test Code

37134

CPT Codes
86255<br /> Limited Access Code

Physician Attestation of Informed Consent

This germline genetic test requires physician attestation that patient consent has been received if ordering medical facility is located in AK, DE, FL, GA, IA, MA, MN, NV, NJ, NY, OR, SD or VT or test is performed in MA.

Includes

If the MOG Antibody, CBA is positive a semi-quantitative titer will be performed at an additional charge (CPT code 86256).

Preferred Specimen

2 mL serum

Minimum Volume

0.5 mL

Other Acceptable Specimens

CSF collected in a plastic screw-cap vial

Instructions

Serum must be separated from whole blood within 48 hours of collection. Please label each specimen tube with two forms of patient identification. These forms of identification must also appear on the requisition form.

Transport Temperature

Refrigerated (cold packs)

Specimen Stability

Room temperature: 72 hours
Refrigerated: 45 days
Frozen: 39 days

Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)

Turbid and/or any suggestion of bacterial contamination is present

Methodology
Cell-based Immunofluorescence Assay

FDA Status
This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Setup Schedule

Set up: As needed; Report available: 3-7 days

Reference Range

See Laboratory Report

Clinical Significance

Neuromyelitis optica (NMO) is an inflammatory disorder predominantly affecting the optic nerves and spinal cord. Limited forms of disease including isolated optic neuritis, brainstem encephalitis and longitudinal extensive transverse myelitis (LETM) or acute disseminated encephalomyelitis (ADEM) have been referred to as NMO spectrum disorder (NMOSD). The majority of individuals with NMO and many with NMOSD have antibodies against aquaporin-4 (AQP4). MOG antibodies have been reported without AQP4 antibodies in individuals with NMO and other non-multiple sclerosis demyelinating diseases. The presence of MOG antibodies in AQP4 antibody negative individuals can help differentiate between multiple sclerosis (MS) and non-MS demyelinating diseases and aid in clinical management decisions.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.